Human Clinical Study Further Indicates FruiteX-B? Calcium Fructoborate Provides Fast-Acting Joint and Flex Benefits - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Human Clinical Study Further Indicates FruiteX-B? Calcium Fructoborate Provides Fast-Acting Joint and Flex Benefits


Human Clinical Study Further Indicates FruiteX-B® Calcium Fructoborate Provides Fast-Acting Joint and Flex Benefits

PR Newswire

MOMENCE, Ill., June 17, 2014 /PRNewswire/ -- FutureCeuticals, Inc. today announced publication of the results of another successful human clinical study on FruiteX-B® calcium fructoborate, a patented plant mineral complex.

The double-blind, placebo-controlled study examined the effects of FruiteX-B® supplementation during fourteen days on subjects with self-reported knee discomfort. The study population was equally divided between generally healthy men and women ranging in ages from 35 to 65. Testing measures included the widely-used WOMAC and McGill questionnaires, standard indices of joint and flex comfort. Analyses of effects were based upon the mean of within-subject changes from baseline values. Results showed that the effect of FruiteX-B® was significantly more efficacious than the placebo.

In as little as 7 days, subjects in the FruiteX-B® group (30 subjects) experienced a 21% improvement in McGill scores (p=0.0025) and a trend toward improvement in WOMAC scores (25% reduction; p=0.06). At 14 days, subjects in the FruiteX-B® group continued to see further significant improvement as measured by both McGill and WOMAC, 27% (p=0.0001) and 29% (p=0.0001) respectively. The placebo group (30 subjects) failed to show statistically significant differences. Statistics were independently reviewed by the Department of Statistics, School of Information and Computer Science, University of California at Irvine.

These results confirm results obtained from a previous study on the proprietary ingredient's fast-acting joint benefits, as measured by McGill and WOMAC, published in 2012.

This study represents one set of data from a broader clinical study on the joint and flex benefits of FruiteX-B® calcium fructoborate. A second set of data on the ability of FruiteX-B® to elicit substantially similar results when combined with glucosamine and chondroitin is currently under review.

"This new study extends our substantial body of peer-reviewed, published clinical work on the unique physiological benefits of FruiteX-B® for joint health," said John M. Hunter, FutureCeuticals' Executive Vice President. "This extraordinary plant mineral complex continues to exhibit best-in-class clinical activity among lead ingredients in the joint space. Its 'take-it, feel-it' benefits, combined with a small, affordable serving (108 mg twice daily), help explain why it has quickly become a key driver of the market's best joint/flex products. We couldn't be happier with these results."

Source: "Clinical Interventions in Aging" 2014:9 895-899 (http://dx.doi.org/10.2147/CIA.S64590)

Article: Short-term efficacy of calcium fructoborate on subjects with knee discomfort: a comparative, double-blind, placebo-controlled clinical study.

Authors: Zbigniew Pietrzkowski, Michael J. Phelan, Robert Keller, Cynthia Shu, Ruby Argumedo, Tania Reyes-Izquierdo

FruiteX-B® Calcium Fructoborate is manufactured under US Patent #5,962,049 and issued and pending foreign patents and is available exclusively from VDF FutureCeuticals, Inc.

About FutureCeuticals, Inc.

FutureCeuticals, Inc. is a vertically integrated functional food ingredient, product development, and bioanalytical research and discovery company with farms and facilities in Illinois, Indiana, Wisconsin, California, and Europe.

FutureCeuticals is a voting member of the Council for Responsible Nutrition, a voting member of the International Probiotics Association, and a proud supporter of the American Botanical Council. 

SOURCE FutureCeuticals, Inc.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document

Click here